Methylation analysis of Gasdermin E shows great promise as a biomarker for colorectal cancer

AberrantGasdermin E (GSDME) methylation in cancer makes it a candidate biomarker gene. This is the first study to thoroughly analyzeGSDME methylation in the largest colorectal adenocarcinoma patient cohort to date (N  = 432) using publicly available data. We identified a combination of CpGs, that can discriminate between colorectal cancer and normal tissue samples with high accuracy (AUC = 0.95). Additionally, we found significant differences inGSDME methylation between left ‐ and right‐sided colorectal cancers. AbstractIn addition to its implication in hereditary hearing loss, theGasdermin E (GSDME) gene is also a tumor suppressor involved in cancer progression through programmed cell death.GSDME epigenetic silencing through methylation has been shown in some cancer types, but studies are yet to fully explore its diagnostic/prognostic potential in colorectal cancer on a large ‐scale. We used public data from The Cancer Genome Atlas (TCGA) to investigate differences inGSDME methylation and expression between colorectal cancer and normal colorectal tissue, and between left ‐ and right‐sided colorectal cancers in 432 samples. We also exploredGSDME's diagnostic capacity as a biomarker for colorectal cancer. We observed differential methylation in all 22GSDME CpGs between tumor and normal tissues, and in 18 CpGs between the left ‐ and right‐sided groups. In the cancer tissue, putative promoter probes were hypermethylated and gene body probes were hypomethylated,...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research